MET and non-small cell lung carcinoma: Currently, several phase I and phase II studies have demonstrated the promising activity of MET tyrosine kinase inhibitors (TKIs), such as tepotinib, capmatinib and savolitinib, in NSCLC patients with c-MET dysregulation [12].